No Data
JW (Cayman) Therapeutics Issues Share Options, RSUs to Two Employees
JW THERAP-B (02126.HK) granted a total of 0.3877 million stock options.
Gelonghui reported on January 6 that JW THERAP-B (02126.HK) announced that on January 6, 2025, (i) a total of 387,740 stock options will be granted at an exercise price of HKD 1.36 per share, according to the terms of the incentive plan adopted after the company's initial public offering on October 14, 2020; and (ii) a total of 77,548 restricted stock units will be granted to two grantees according to the restricted stock unit plan adopted after the company's initial public offering on October 14, 2020.
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
Express News | The USA Biological Security Act was not included in the CR bill.
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
The chapter comes to a close! The final version of the NDAA in both the House and Senate did not include the biological security bill. Will it make a comeback next year?
1. The final negotiation text of NDAA did not include the "Biosecurity Act", and the attempt to "ride on the coattails" failed again; 2. This year, the session of the US Congress will come to an end, experts believe that the legislation of the "Biosecurity Act" this year may come to a conclusion, but it may "come back with a vengeance" next year.
